Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdministrative changes: addition of revision v3.4.2 and removal of prior notices (including the lapse funding notice and revision v3.4.1); these updates do not affect study details, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status has been added, including a link to cc.nih.gov and opm.gov. Revision metadata now shows Revision: v3.4.1 with dates 2026-02-03, 2026-01-30, and 2026-01, replacing Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedShow glossary toggle added to provide definitions for terms used in the study details. The page now displays updated metadata labels, including a new Revision: v3.4.0 and Last Update Posted, with minor formatting adjustments to related fields such as No FEAR Act Data.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page revision label changed from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check64 days agoChange DetectedUpdated the study locations: new sites across multiple regions have been added and some sites removed, resulting in revised location availability and contact details on the Study Details page.SummaryDifference1%

- Check85 days agoChange DetectedThe revision label updated from v3.3.1 to v3.3.2; no visible changes to study content.SummaryDifference0.0%

Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.